Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Petosemtamab · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Petosemtamab + Pembrolizumab | EXPERIMENTAL | Combination Therapy |
| Pembrolizumab | ACTIVE_COMPARATOR | Monotherapy |
| MCLA-158 | EXPERIMENTAL | - |
| Investigator's Choice | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Petosemtamab | DRUG | MCLA-158 |
| Pembrolizumab | DRUG | Humanized Antibody |
| Investigator's Choice | DRUG | Cetuximab |
Inclusion Criteria: 1. Signed ICF before initiation of any study procedures 2. Age ≥ 18 years at signing of ICF 3. Histologically confirmed HNSCC with evidence of metastatic or locally recurrent disease not amenable to local therapy with curative intent. 4. The eligible HNSCC primary tumor location...
Petosemtamab is an investigational antibody being studied for the treatment of Head and Neck Squamous Cell Carcinoma. It is currently in Phase 3 clinical trials for this indication, including as a monotherapy in previously treated patients and in combination with pembrolizumab as a first-line treatment.
Petosemtamab is a monoclonal antibody, indicated by its -mab suffix. It is being developed by Merus N.V. for oncology applications, specifically targeting Head and Neck Squamous Cell Carcinoma. The specific molecular target has not been disclosed in the available clinical trial information.
Petosemtamab is being developed by Merus N.V., a biopharmaceutical company listed on the NASDAQ under the ticker symbol MRUS. The company is conducting Phase 3 clinical trials for this drug in Head and Neck Squamous Cell Carcinoma.
Petosemtamab is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. It has received Breakthrough Therapy and Fast Track designations from the FDA for its development in Head and Neck Squamous Cell Carcinoma.
Petosemtamab is being evaluated in two Phase 3 trials. NCT06496178 compares petosemtamab to investigator's choice monotherapy in previously treated Head and Neck Squamous Cell Carcinoma patients. NCT06525220 evaluates petosemtamab plus pembrolizumab versus pembrolizumab alone as first-line treatment. Both trials are active, with a combined enrollment of about 1,300 patients.
No, Petosemtamab is not the same as pembrolizumab. Petosemtamab is an investigational antibody being developed by Merus N.V., while pembrolizumab is a separate, approved immunotherapy. In one Phase 3 trial, petosemtamab is being studied in combination with pembrolizumab, but they are distinct drugs.